Dawn E. Quelle

Dawn E. Quelle

University of Iowa

H-index: 33

North America-United States

About Dawn E. Quelle

Dawn E. Quelle, With an exceptional h-index of 33 and a recent h-index of 20 (since 2020), a distinguished researcher at University of Iowa, specializes in the field of cancer biology, Iowa Neuroscience and Pharmacology.

His recent articles reflect a diverse array of research interests and contributions to the field:

A systematic NEN spheroid drug screen reveals a novel drug resistance mechanism in small bowel NETs

FOXM1, MEK, and CDK4/6: New targets for MPNST therapy

Inhibition of serotonin biosynthesis in neuroendocrine neoplasm suppresses tumor growth in vivo

Therapies targeting CDK4/6 cause regression, immune cell activation, and sensitization to PD-L1 immunotherapy in pancreatic neuroendocrine tumors

CDK4/6-MEK Targeted Therapy Causes Regression and Reduced Metastatic Colonization of Pancreatic Neuroendocrine Tumors

Investigating serotonin metabolism in neuroendocrine cancers

FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy

CDK4/6-MEK inhibition in MPNSTs causes plasma cell infiltration, sensitization to PD-L1 blockade, and tumor regression

Dawn E. Quelle Information

University

Position

Professor of Neuroscience and Pharmacology

Citations(all)

11365

Citations(since 2020)

1593

Cited By

10153

hIndex(all)

33

hIndex(since 2020)

20

i10Index(all)

54

i10Index(since 2020)

36

Email

University Profile Page

University of Iowa

Google Scholar

View Google Scholar Profile

Dawn E. Quelle Skills & Research Interests

cancer biology

Iowa Neuroscience and Pharmacology

Top articles of Dawn E. Quelle

Title

Journal

Author(s)

Publication Date

A systematic NEN spheroid drug screen reveals a novel drug resistance mechanism in small bowel NETs

Cancer Research

Catherine G Tran

Luis C Borbon

Dane H Tow

Jonathan Shilyansky

Guiying Li

...

2024/3/22

FOXM1, MEK, and CDK4/6: New targets for MPNST therapy

Ellen Voigt

Dawn E Quelle

2023/8/2

Inhibition of serotonin biosynthesis in neuroendocrine neoplasm suppresses tumor growth in vivo

bioRxiv

Dane H Tow

Catherine G Tran

Luis C Borbon

Maclain Ridder

Guiying Li

...

2023/4/8

Therapies targeting CDK4/6 cause regression, immune cell activation, and sensitization to PD-L1 immunotherapy in pancreatic neuroendocrine tumors

Endocrine Abstracts

Courtney Kaemmer

Shaikamjad Umesalma

Chandra Maharjan

Jordan Kohlmeyer

Joshua Lingo

...

2023/12/15

CDK4/6-MEK Targeted Therapy Causes Regression and Reduced Metastatic Colonization of Pancreatic Neuroendocrine Tumors

Endocrine Abstracts

Courtney Kaemmer

Shaikamjad Umesalma

Chandra Maharjan

Jordan Kohlmeyer

Emily Wilkerson

...

2023/2/1

Investigating serotonin metabolism in neuroendocrine cancers

Endocrine Abstracts

Dane H Tow

Maclain Ridder

Catherine G Tran

Luis C Borbon

Guiying Li

...

2023/12/15

FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy

Ellen Voigt

Dawn E Quelle

2023/9/2

CDK4/6-MEK inhibition in MPNSTs causes plasma cell infiltration, sensitization to PD-L1 blockade, and tumor regression

Clinical cancer research

Jordan L Kohlmeyer

Joshua J Lingo

Courtney A Kaemmer

Amanda Scherer

Akshaya Warrier

...

2023/9/1

Utility of CD138/syndecan-1 immunohistochemistry for localization of plasmacytes is tissue-dependent in B6 mice

BMC research notes

David K Meyerholz

Mariah R Leidinger

J Adam Goeken

Thomas R Businga

Allison Akers

...

2022/6/25

Development of a Real-Time Luminescent Sensor for Detecting Serotonin Levels in Neuroendocrine Tumors

Dane Tow

Deeraj Manika

Courtney A Kaemmer

Michael Henry

Dawn Quelle

...

2022/3/1

Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo

Neuro-oncology advances

Jordan L Kohlmeyer

Courtney A Kaemmer

Joshua J Lingo

Ellen Voigt

Mariah R Leidinger

...

2022/1/1

Abstract A02: MEK-CDK4/6 inhibition induces plasma cell tumor infiltration and sensitizes de novo MPNSTs to immune checkpoint blockade

Cancer immunology research

Joshua Lingo

Jordan Kohlmeyer

Courtney Kaemmer

Amanda Scherer

Ellen Voigt

...

2022/12/1

Preclinical models of neuroendocrine neoplasia

Andrew JH Sedlack

Kimia Saleh-Anaraki

Suresh Kumar

Po Hien Ear

Kate E Lines

...

2022/11/17

Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism

JCI insight

Wade R Gutierrez

Amanda Scherer

Jeffrey D Rytlewski

Emily A Laverty

Alexa P Sheehan

...

2022/11/11

RABL6A regulates schwann cell senescence in an RB1-dependent manner

International journal of molecular sciences

Jordan L Kohlmeyer

Courtney A Kaemmer

Shaikamjad Umesalma

Francoise A Gourronc

Aloysius J Klingelhutz

...

2021/5/20

Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis

Scientific reports

Courtney A Kaemmer

Shaikamjad Umesalma

Chandra K Maharjan

Devon L Moose

Goutham Narla

...

2021/5/13

Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas

Oncotarget

Chandni Desai

Jon Thomason

Jordan L Kohlmeyer

Anna C Reisetter

Parmanand Ahirwar

...

2021/4/4

Combination therapies for MPNSTs targeting RABL6A-RB1 signaling

Oncotarget

Jordan L Kohlmeyer

David J Gordon

Munir R Tanas

Rebecca D Dodd

Varun Monga

...

2021/1/1

Pancreatic neuroendocrine tumors: molecular mechanisms and therapeutic targets

Chandra K Maharjan

Po Hien Ear

Catherine G Tran

James R Howe

Chandrikha Chandrasekharan

...

2021/10/12

RABL6A promotes pancreatic neuroendocrine tumor angiogenesis and progression in vivo

Biomedicines

Chandra K Maharjan

Shaikamjad Umesalma

Courtney A Kaemmer

Viviane P Muniz

Casey Bauchle

...

2021/6/2

See List of Professors in Dawn E. Quelle University(University of Iowa)